📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-30 20:35
204 analysed today
FollowTelegram
204
Today
150,155
All-time analysed
43,030
Positive
6,675
Negative
91,727
Neutral
8,655
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
21 announcements match the current filters (relevance ≥ 5).
Vineet Laboratories Statutory Auditor NSVR & Associates Resigns Effective Sept 29, 2026
Vineet Laboratories Limited announced the resignation of its statutory auditor, M/s. NSVR & Associates LLP, effective from the close of business hours on September 29, 2026. The auditor had completed the audit for FY2026 (issuing their report on August 25, 2026) out of an original 5-year tenure scheduled through the 11th AGM. The stated reasons for resignation are preoccupation with other assignments, time constraints, and cost considerations to the audit firm, with no reported disputes or information withholding.
Confidence: HIGH
What changedStatutory Auditor NSVR & Associates LLP has resigned prematurely before completing their 5-year mandate.
Why it mattersMid-term statutory auditor resignations require scrutiny regarding governance and continuity, although the auditor explicitly denied disputes or audit evidence issues.
Original appointment date: September 28, 2022Effective date of resignation: September 29, 2026Date of latest audit report issued: 25-08-2026
📅 Short termMay prompt market caution pending appointment of a new reputable audit firm before upcoming quarterly filings.
📈 Long termLimited operational impact if a credible replacement auditor is onboarded smoothly without audit qualifications.
⚠ Risk flags
- Mid-term auditor departure
- Low promoter holding (5.98% as of June 2026)
Key Highlights
Resignation effective from the closing of business hours on September 29, 2026
Auditor appointed on September 28, 2022, for a 5-year term ending at the 11th AGM
Latest audit report for the year ending March 31, 2026, submitted on August 25, 2026
Reasons cited include preoccupation with other assignments, constraints of time, and cost considerations
👀 What to Watch
Track the upcoming Board and Audit Committee meetings for the recommendation and shareholder approval of a successor statutory auditor.
Vineet Labs Reports FY26 PBT of ₹1.28 Cr vs ₹20.78 Cr Loss; Equity Infusion of ₹29.08 Cr
Vineet Laboratories reported its audited standalone financial results for FY26, turning around with a Profit Before Tax (PBT) of ₹1.28 Cr compared to a loss of ₹20.78 Cr in FY25. The company completed a share issuance during the year, raising ₹29.08 Cr in net proceeds and expanding total equity to ₹45.60 Cr from ₹14.65 Cr. However, operating cash flow turned negative at -₹12.03 Cr (vs +₹11.49 Cr in FY25), driven primarily by working capital tie-up with inventory rising to ₹64.09 Cr. Cash and cash equivalents closed at ₹16.70 Cr at the end of FY26.
Confidence: HIGH
What changedVineet Laboratories published its audited FY26 annual accounts with an unmodified audit opinion, showing a return to PBT profitability and balance sheet recapitalization via equity issue.
Why it mattersThe ₹29.08 Cr equity raise bolsters the balance sheet and liquidity (cash of ₹16.70 Cr), helping offset past losses, though working capital cash absorption remains high.
FY26 Profit Before Tax: ₹128.27 LakhsFY25 Profit Before Tax: -₹2,077.55 LakhsProceeds from share issuance: ₹2,908.18 LakhsOperating cash flow FY26: -₹1,203.19 LakhsClosing cash & cash equivalents: ₹1,669.52 LakhsTotal Equity (Net Worth): ₹4,560.19 Lakhs
📅 Short termMarket sentiment should view the return to net profitability and reinforced equity cushion positively, though delayed annual filing timing remains a slight drag.
📈 Long termLong-term viability will depend on stabilizing operating margins in API intermediates, reducing high China dependency, and converting inventory into cash flows.
⚠ Risk flags
- Operating cash outflow of -₹12.03 Cr in FY26 due to working capital lock-up
- Inventory increased 28.3% to ₹64.09 Cr, increasing working capital intensity
- Delayed annual result filing in August 2026
Key Highlights
FY26 PBT turned positive to ₹1.28 Cr (₹128.27 Lakhs) from a loss of ₹20.78 Cr (₹2,077.55 Lakhs) in FY25
Proceeds from share issuance contributed ₹29.08 Cr (₹2,908.18 Lakhs), lifting total equity to ₹45.60 Cr
Cash and cash equivalents increased sharply to ₹16.70 Cr (₹1,669.52 Lakhs) vs ₹0.31 Cr in FY25
Operating cash flow turned negative to -₹12.03 Cr (-₹1,203.19 Lakhs) due to inventory accumulation to ₹64.09 Cr
Statutory auditor NSVR & Associates LLP issued an unmodified audit opinion
👀 What to Watch
Track working capital unwinding and quarterly revenue consistency in upcoming FY27 quarters to verify sustained operational recovery.
Vineet Labs FY26 Audited Results: PBT Turns Positive at ₹1.28 Cr; Infuses ₹29.08 Cr Equity
Vineet Laboratories approved its audited standalone financial results for FY26, reporting a turnaround in Profit Before Tax to ₹1.28 Cr compared to a loss of ₹20.78 Cr in FY25. The company's net worth expanded significantly to ₹45.60 Cr (up from ₹14.65 Cr), bolstered by ₹29.08 Cr raised via fresh equity issuance. However, cash flow from operations turned negative at -₹12.03 Cr (compared to +₹11.49 Cr in FY25) due to working capital tie-up as inventories increased to ₹64.09 Cr. Cash and bank balances stood higher at ₹16.70 Cr at the end of the year.
Confidence: HIGH
What changedVineet Laboratories reported its audited FY26 annual results, confirming operational turnaround to modest profitability and balance sheet recapitalization.
Why it mattersThe ₹29.08 Cr equity infusion relieves severe balance sheet strain, though high working capital absorption continues to constrain operational cash generation.
FY26 Profit Before Tax: ₹1.28 CrShare Issuance Proceeds: ₹29.08 CrOperating Cash Flow (FY26): ₹-12.03 CrClosing Cash & Equivalents: ₹16.70 CrInventory as of March 31, 2026: ₹64.09 Cr
📅 Short termThe return to positive annual profitability and improved liquidity position from equity proceeds provide near-term stability.
📈 Long termLong-term trajectory depends on improving return ratios, managing working capital cycles, and scaling API intermediate volumes sustainably.
⚠ Risk flags
- Negative operating cash flows of -₹12.03 Cr in FY26
- High working capital blockage with inventory rising to ₹64.09 Cr
- Low promoter holding (~6.0%)
Key Highlights
Profit Before Tax turned positive at ₹1.28 Cr in FY26 compared to a loss of ₹20.78 Cr in FY25
Raised ₹29.08 Cr via issuance of shares, expanding total equity to ₹45.60 Cr from ₹14.65 Cr
Cash and cash equivalents increased to ₹16.70 Cr as of March 31, 2026, up from ₹0.31 Cr
Operating cash flow deteriorated to -₹12.03 Cr driven by inventory expansion to ₹64.09 Cr
Statutory auditor NSVR & Associates LLP issued an unmodified audit opinion
👀 What to Watch
Monitor upcoming quarterly results to verify whether profitability is sustainable and whether the high inventory base of ₹64.09 Cr can be monetized to generate positive operational cash flows.
MD Gaddam Venkata Ramana steps down; remains Non-Executive Director
Mr. Gaddam Venkata Ramana has ceased to be the Managing Director of Vineet Laboratories effective July 21, 2026. While he steps down from the executive role, he will continue to serve as a Non-Executive Director on the board. This leadership transition occurs at a critical time for the company, which is currently grappling with a TTM net loss of ‑Rs 10 Cr and a high Debt-to-Equity ratio of 3.07. Furthermore, promoter holding has seen a sharp decline from 15.89% in September 2025 to 5.98% by March 2026.
Confidence: HIGH
What changedThe Managing Director has transitioned from an executive leadership role to a Non-Executive Director position.
Why it mattersLeadership changes in micro-cap companies (Rs 73 Cr market cap) with high leverage and declining promoter skin-in-the-game often signal internal restructuring or potential shifts in control.
Shares held by outgoing MD: 4,71,000 unitsPromoter Holding (Mar 2026): 5.98%Debt-to-Equity Ratio: 3.07TTM Net Profit: ‑Rs 10 CrOperating Profit Margin: -9.3%
📅 Short termThe stock may remain volatile as the market assesses the impact of the MD's departure from executive duties amidst weak financial performance.
📈 Long termThe structural concern remains the company's high debt and 80% dependency on China for raw materials; leadership stability is crucial for navigating these risks.
⚠ Risk flags
- High Debt-to-Equity ratio of 3.07
- Significant decline in promoter holding (from 15.89% to 5.98%)
- Negative operating margins and consistent losses
Key Highlights
Mr. Gaddam Venkata Ramana ceased to be Managing Director effective July 21, 2026
The outgoing MD holds 4,71,000 equity shares in the company as of the transition date
Promoter holding has significantly decreased to 5.98% as of March 2026 from 15.89% in September 2025
Company reported a TTM net loss of ‑Rs 10 Cr on a revenue base of Rs 55 Cr
Debt remains high at Rs 43 Cr against a net worth of only Rs 14 Cr
👀 What to Watch
Investors should monitor the appointment of a successor and observe if the leadership change leads to a strategy for debt reduction and operational turnaround, given the negative OPM of -9.3%.
Vineet Laboratories Defers FY26 Audited Financial Results; Company Secretary Resigns
Vineet Laboratories has postponed the consideration and approval of its audited standalone financial results for the quarter and year ended March 31, 2026. The deferment occurred because the Audit Committee did not recommend the results to the Board during the meeting held on May 30, 2026. Furthermore, the company announced the resignation of its Company Secretary and Compliance Officer. The trading window for dealing in the company's equity shares will remain closed until 48 hours after the results are eventually declared.
Key Highlights
Audited financial results for the fiscal year ended March 31, 2026, have been officially deferred.
The Board meeting held on May 30, 2026, failed to approve results as the Audit Committee did not recommend them.
Resignation of the Company Secretary and Compliance Officer was formally communicated to the Board.
Trading window remains closed for all designated persons until 48 hours post-result declaration.
A revised date for the Audit Committee and Board Meeting will be intimated in due course.
👀 What to Watch
Investors should remain cautious as the delay in reporting year-end results alongside the exit of a compliance officer can be a red flag for governance or accounting issues. Await the revised meeting date and the eventual financial disclosures to assess the company's health.
Vineet Laboratories Q3 FY26: Turnaround to ₹85 Lakh Profit; Revenue Down 13.5% YoY
Vineet Laboratories reported a significant turnaround in Q3 FY26, posting a net profit of ₹85.07 Lakhs compared to a net loss of ₹570.70 Lakhs in the same period last year. This recovery occurred despite a 13.5% year-on-year decline in revenue from operations, which stood at ₹1,564.83 Lakhs. The board also ratified advances for Quality Control and RO water equipment for its new facility, noting these were not specifically mentioned in the December 2025 Rights Issue Letter of Offer. For the nine-month period ending December 2025, the company has returned to profitability with a net profit of ₹38.56 Lakhs.
Key Highlights
Net Profit of ₹85.07 Lakhs in Q3 FY26 vs a Net Loss of ₹570.70 Lakhs in Q3 FY25.
Revenue from operations decreased to ₹1,564.83 Lakhs from ₹1,809.93 Lakhs YoY.
Total expenses significantly reduced to ₹1,487.79 Lakhs from ₹2,380.59 Lakhs in the previous year's quarter.
Earnings Per Share (EPS) improved to ₹0.92 from a negative ₹6.19 YoY.
Board ratified equipment advances for the new production facility, deviating from the specific objects of the recent Rights Issue.
👀 What to Watch
While the turnaround to profitability is a strong positive, investors should monitor the declining revenue trend and the execution of the new production facility. Watch for whether the cost-cutting measures that led to this profit are sustainable in the long term.
Vineet Laboratories Q3 Results: PAT at ₹85.07 Lakhs, Turnaround from YoY Loss
Vineet Laboratories reported a net profit of ₹85.07 Lakhs for the quarter ended December 31, 2025, marking a significant turnaround from a net loss of ₹570.70 Lakhs in the same period last year. Although revenue from operations declined by 13.5% YoY to ₹1,564.83 Lakhs, the company achieved profitability through improved cost efficiencies. For the nine-month period, the company turned profitable with a PAT of ₹38.56 Lakhs compared to a loss of ₹966.61 Lakhs in the previous year. The board also ratified payments for new equipment intended for the production facility mentioned in their recent Rights Issue.
Key Highlights
Net Profit of ₹85.07 Lakhs in Q3 FY26 vs a loss of ₹570.70 Lakhs in Q3 FY25
Revenue from operations stood at ₹1,564.83 Lakhs, down from ₹1,809.93 Lakhs YoY
Nine-month (9M) PAT turned positive at ₹38.56 Lakhs against a loss of ₹966.61 Lakhs in 9M FY25
Earnings Per Share (EPS) improved to ₹0.92 from a negative ₹6.19 YoY
Board ratified advances for Quality Control and RO equipment for a new production facility
👀 What to Watch
The company has successfully transitioned back to profitability despite a declining top line, suggesting improved operational margins. Investors should watch for revenue scaling once the new production facility and equipment are fully operational.
Vineet Laboratories Gets Trading Approval for 99.87 Lakh Rights Issue Shares
Vineet Laboratories Limited has received final trading approvals from both BSE and NSE for 99,87,258 equity shares allotted under its recent Rights Issue. These shares, issued at a price of Rs. 30 each (Rs. 10 face value plus Rs. 20 premium), are set to commence trading on February 05, 2026. This announcement marks the successful completion of the fundraising process, providing liquidity to the newly issued shares. Investors should be aware that the total outstanding equity has increased, which may lead to dilution of earnings per share (EPS).
Key Highlights
Received trading approval for 99,87,258 equity shares from BSE and NSE.
Shares issued at Rs. 30 per share, including a premium of Rs. 20.
Trading of the new shares is effective from Thursday, February 05, 2026.
Distinctive numbers for the new shares range from 9219009 to 19206266.
👀 What to Watch
Shareholders who were allotted shares in the rights issue can now trade them on the exchanges. Monitor the stock for potential short-term price volatility as the new supply of shares enters the secondary market.
Vineet Laboratories Allots 99.87 Lakh Equity Shares via Rights Issue at Rs 30 Per Share
Vineet Laboratories has successfully completed its rights issue by allotting 99,87,258 equity shares at a price of Rs 30 per share (including a premium of Rs 20). This capital infusion has raised approximately Rs 29.96 crore for the company. Consequently, the total paid-up equity share capital has more than doubled, increasing from Rs 9.22 crore to Rs 19.21 crore. The allotment follows the terms set in the Letter of Offer dated December 17, 2025.
Key Highlights
Allotment of 99,87,258 equity shares of face value Rs 10 each on a rights basis.
Issue price fixed at Rs 30 per share, representing a total fundraise of approx Rs 29.96 crore.
Total number of equity shares increased from 92,19,008 to 1,92,06,266 post-allotment.
Paid-up share capital expanded from Rs 9,21,90,080 to Rs 19,20,62,660.
The allotment was finalized in consultation with Bigshare Services Private Limited and BSE Limited.
👀 What to Watch
Investors should track the company's upcoming quarterly results to see how the newly raised capital is deployed for growth. While the capital infusion is positive, shareholders should be aware of the significant equity dilution as the share count has more than doubled.
Vineet Laboratories Extends Rights Issue Closing Date to January 30, 2026
Vineet Laboratories Limited has announced an extension of its ongoing Rights Issue timeline following a committee meeting on January 13, 2026. The last date for On-Market Renunciation has been moved to January 27, 2026, while the overall Issue Closing Date is now January 30, 2026. This extension is intended to provide more time for investors to participate in the fundraising process. Following the closure, the basis of allotment and listing of shares are scheduled for February 2 and February 3, 2026, respectively.
Key Highlights
Last date for On-Market Renunciation of Rights Entitlements extended to January 27, 2026
Rights Issue closing date officially extended to January 30, 2026
Basis of Allotment and Allotment of Shares scheduled for February 2, 2026
Listing of new Equity Shares on BSE and NSE expected by February 3, 2026
👀 What to Watch
Investors holding Rights Entitlements (REs) should ensure they either subscribe to the issue or sell their REs on the market by January 27 to avoid total value loss. Monitor the share price relative to the rights price to determine if subscription is financially viable.
Vineet Laboratories to Raise ₹29.97 Crore via Rights Issue at ₹30 Per Share
Vineet Laboratories Limited has submitted its Letter of Offer for a Rights Issue aiming to raise approximately ₹29.97 crore. The company will issue 99,87,258 equity shares at a price of ₹30 per share, which includes a premium of ₹20. The rights entitlement ratio is fixed at 13 shares for every 12 shares held by eligible shareholders as of the record date, December 23, 2025. The issue is scheduled to open on January 1, 2026, and close on January 21, 2026.
Key Highlights
Rights issue size of up to 99,87,258 shares aggregating to ₹29.97 Crores
Issue price set at ₹30 per share (Face Value ₹10 + Premium ₹20)
Rights entitlement ratio of 13:12 for shareholders as of December 23, 2025
Subscription period opens on January 01, 2026, and closes on January 21, 2026
On-market renunciation period ends on January 16, 2026
👀 What to Watch
Existing shareholders should monitor the market price relative to the ₹30 offer price and decide whether to subscribe, renounce, or sell their rights entitlements before the January 16 deadline.
Vineet Laboratories Announces ₹29.96 Cr Rights Issue; Record Date Dec 23, 2025
Vineet Laboratories has finalized the terms for its Rights Issue, aiming to raise approximately ₹29.96 crores by issuing 99,87,258 equity shares. The issue price is fixed at ₹30 per share, and the record date for determining eligible shareholders is December 23, 2025. The entitlement ratio is set at 13:12, which will significantly expand the company's equity base from 92.19 lakh shares to 1.92 crore shares upon full subscription. The issue is scheduled to open on January 1, 2026, and close on January 21, 2026.
Key Highlights
Rights Issue size of ₹29.96 crores involving 99,87,258 fully paid-up equity shares.
Issue price set at ₹30 per share, including a premium of ₹20 per share.
Entitlement ratio of 13 Rights Equity Shares for every 12 Equity Shares held as of the record date.
Record date for eligibility is December 23, 2025; Issue period runs from Jan 1 to Jan 21, 2026.
Post-issue equity capital to increase from 92,19,008 to 1,92,06,266 shares assuming full subscription.
👀 What to Watch
Investors should compare the current market price with the ₹30 issue price to determine if the rights offer is attractive. Existing shareholders must ensure they hold shares by the record date to receive entitlements, which they can either subscribe to or renounce.
Vineet Laboratories to Raise ₹29.96 Cr via Rights Issue at ₹30 per Share
Vineet Laboratories Limited has approved a rights issue to raise approximately ₹29.96 crore through the issuance of 99,87,258 equity shares. The issue price is set at ₹30 per share, which is payable in full upon application. Shareholders as of the record date, December 23, 2025, will be entitled to 13 new shares for every 12 shares held. The subscription period is scheduled to run from January 1, 2026, to January 21, 2026.
Key Highlights
Total rights issue size of ₹29.96 crore involving 99,87,258 equity shares.
Issue price fixed at ₹30 per share (₹10 face value + ₹20 premium).
Rights entitlement ratio set at 13:12 for eligible shareholders.
Record date for eligibility is December 23, 2025; Issue opens January 1, 2026.
Post-issue equity base will increase from 92.19 lakh to 1.92 crore shares assuming full subscription.
👀 What to Watch
Existing shareholders should compare the ₹30 issue price with the current market price to decide whether to subscribe, renounce, or sell their rights entitlements to mitigate the impact of significant equity dilution.
Vineet Laboratories Receives BSE and NSE Approval for Rs 30 Crore Rights Issue
Vineet Laboratories Limited has secured in-principle approvals from both the National Stock Exchange (NSE) and BSE Limited to undertake a Rights Issue of fully paid-up equity shares. The company plans to raise up to Rs 30 Crores through this issue, offering shares with a face value of Rs 10 each. A board meeting is scheduled for December 17, 2025, to finalize the issue price, entitlement ratio, and record date. This capital infusion is expected to strengthen the company's balance sheet, though it will result in equity dilution for existing shareholders who do not participate.
Key Highlights
Received in-principle approval from NSE on December 02, 2025, and BSE on December 16, 2025.
The proposed Rights Issue aims to aggregate up to a total of Rs 30 Crores.
Board meeting scheduled for December 17, 2025, to determine the issue price, entitlement ratio, and record date.
The issue involves fully paid-up equity shares with a face value of Rs 10 each.
👀 What to Watch
Existing shareholders should wait for the announcement of the issue price and entitlement ratio to assess the discount offered compared to the market price. Investors should decide whether to subscribe to avoid dilution or sell their rights entitlements if the company allows renunciation.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to Dec 17 for Price Finalization
Vineet Laboratories Limited has adjourned its Rights Issue Committee meeting from December 16 to December 17, 2025. The committee is scheduled to finalize critical details including the Issue Price, Entitlement Ratio, and Record Date for the proposed capital raise. This delay is intended to facilitate the receipt of in-principle approval from BSE Limited. Investors should monitor the upcoming announcement as it will define the terms of equity dilution and the cost of new shares.
Key Highlights
Rights Issue Committee meeting adjourned from December 16 to December 17, 2025.
Committee to determine key modalities: Issue Price, Entitlement Ratio, and Record Date.
Finalization is subject to receiving in-principle approval from BSE Limited.
The initial meeting on December 16 lasted only 30 minutes (6:20 P.M. to 6:50 P.M.) before adjournment.
👀 What to Watch
Wait for the finalized terms on December 17 to evaluate the attractiveness of the rights issue price compared to the current market price. Assess the potential dilution effect once the entitlement ratio is announced.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to December 16, 2025
Vineet Laboratories Limited has adjourned its Rights Issue Committee meeting, originally scheduled for December 15, 2025, to December 16, 2025. The committee is expected to finalize critical details including the Issue Price, Entitlement Ratio, and Record Date for the upcoming rights issue. This adjournment is intended to allow time for the receipt of in-principle approval from the BSE. The meeting on December 15 lasted only 20 minutes before the decision to adjourn was made.
Key Highlights
Rights Issue Committee meeting adjourned from December 15 to December 16, 2025
Committee to determine Issue Price, Entitlement Ratio, and Record Date
Adjournment pending in-principle approval from BSE Ltd
The initial meeting on December 15 commenced at 7:00 PM and was adjourned at 7:20 PM
👀 What to Watch
Investors should wait for the adjourned meeting's outcome on December 16 to understand the pricing and dilution impact of the rights issue. Compare the announced issue price with the current market price to determine the attractiveness of the offer.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to December 15, 2025
Vineet Laboratories Limited has adjourned its Rights Issue Committee meeting, originally scheduled for December 12, 2025, to Monday, December 15, 2025. The committee is set to finalize critical parameters of the proposed Rights Issue, including the Issue Price, Entitlement Ratio, and Record Date. This delay is primarily to await the in-principle approval from BSE Limited. The brief 30-minute session on Friday was a procedural commencement before the adjournment was announced.
Key Highlights
Rights Issue Committee meeting adjourned from December 12 to December 15, 2025.
Meeting will determine the Issue Price, Entitlement Ratio, and Record Date for the fundraise.
Adjournment is necessitated by the pending in-principle approval from BSE Ltd.
The original meeting commenced at 6:00 P.M. and was adjourned by 6:30 P.M. on the same day.
Final modalities of the Rights Issue are subject to regulatory approvals and committee decisions.
👀 What to Watch
Investors should wait for the December 15 announcement to assess the Issue Price and Entitlement Ratio, which will determine the potential dilution and cost of participation.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to December 12, 2025
Vineet Laboratories Limited has announced the adjournment of its Rights Issue Committee meeting, originally scheduled for December 11, 2025, to December 12, 2025. The committee is expected to finalize critical terms of the proposed fundraising, including the Issue Price, Entitlement Ratio, and Record Date. This delay is reportedly to facilitate the receipt of in-principle approval from BSE Ltd. The initial meeting on December 11 lasted only 20 minutes before the adjournment was called.
Key Highlights
Rights Issue Committee meeting adjourned from December 11 to December 12, 2025
Committee to determine Issue Price, Entitlement Ratio, and Record Date for the proposed Rights Issue
Finalization is subject to receiving in-principle approval from BSE Ltd
The meeting on December 11 commenced at 6:00 PM and was adjourned by 6:20 PM
👀 What to Watch
Investors should wait for the adjourned meeting's outcome on December 12 to evaluate the rights issue price and potential equity dilution.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to Dec 11, 2025
Vineet Laboratories Limited has adjourned its Rights Issue Committee meeting, which was originally scheduled for December 9, 2025. The meeting is now set to reconvene on Thursday, December 11, 2025, to finalize the terms of the proposed fundraising. The committee is expected to determine the Issue Price, Entitlement Ratio, and Record Date during this session. This adjournment is necessary to await the in-principle approval from the BSE Limited.
Key Highlights
Rights Issue Committee meeting adjourned from December 9 to December 11, 2025
Meeting will finalize critical details including Issue Price and Entitlement Ratio
Adjournment is pending the receipt of in-principle approval from BSE Ltd
The initial meeting on December 9 lasted only 20 minutes before adjournment
👀 What to Watch
Investors should monitor the upcoming announcement on December 11 for specific rights issue terms. Evaluate the issue price relative to the current market price to determine the attractiveness of the offer.
Vineet Laboratories Adjourns Rights Issue Committee Meeting to December 9, 2025
Vineet Laboratories Limited has announced the adjournment of its Rights Issue Committee meeting, originally scheduled for December 6, 2025. The meeting is now rescheduled for Tuesday, December 9, 2025, as the company awaits in-principle approval from BSE Limited. During the upcoming session, the committee is expected to finalize critical details including the Issue Price, Entitlement Ratio, and Record Date. This fundraise is a significant event for the company's capital structure and liquidity.
Key Highlights
Rights Issue Committee meeting adjourned from December 6 to December 9, 2025
Committee to decide on Issue Price, Entitlement Ratio, and Record Date
Adjournment necessitated by pending In-principle approval from BSE Ltd
The initial meeting on Dec 6 lasted only 30 minutes before being adjourned
👀 What to Watch
Investors should monitor the announcement on December 9 for the rights issue price and ratio to assess potential dilution and investment value.
